What did TRUSCREEN GROUP LIMITED announce?

TRUSCREEN GROUP LIMITED (NZX: TRU) filed “Change of Auditor” with NZX on 18 November 2026, as an NZX announcement.

When was it filed?
18 November 2026
Where is the original?
NZX announcement
TRUSCREEN GROUP LIMITED logo

Change of Auditor

Other18 November 2026TRUIndustrials

NZX/ASX Announcement
18 November 2026

Change of Auditors

Truscreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) advises that Mr Vinay Sheoran, an audit partner

who conducts audits through Hall Chadwick (NSW) has retired as an auditor.

Mr Drew Townsend, who conducts audits through Hall Chadwick (NSW) will replace Mr Vinay Sheoran as the registered

audit provider for Truscreen, in compliance with Financial Markets Conduct (FMC) reporting requirements.

Authorised by the Board for filing with the NZX/ASX.

For more information, visit www.truscreen.com or contact:

Tony Ho

Executive Chairman

tonyho@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com

A

bout TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures




an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low

level of optical and electrical stimuli.

TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of

biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel

and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra

®

, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA

(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico).

It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has

distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices

marketed and sold in China.

TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China

Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical

List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines

for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date,

over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi

Arabia. TruScreen’s vision is “A world without the cervical cancer”.

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.


About DaltonBio:


DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro

diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV)

nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits

(DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture

technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This

technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.

DALTONbio’s exceptional, clinically proven products have served tens of millions of lives in the world. They

have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively,

resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.